Scott Henry, CFA

Managing Director, Senior Research Analyst & Head of Pharmaceuticals Research



Scott Henry is a Managing Director, Senior Research Analyst, and the Head of Pharmaceuticals Research covering the Specialty Pharmaceuticals sector at ROTH MKM. Prior to joining Roth Capital Partners, he worked at Oppenheimer, where he led coverage of the US pharmaceutical sector, bringing approximately 12 years of sell-side experience. He has also been affiliated with Thomas Weisel Partners, ABN AMRO, and Leerink Swann & Co.

With expertise in pharmaceuticals, large-cap pharmaceuticals, biotech, and selective medical device names, Mr. Henry has received several awards for his research and analysis. He was ranked #2 in the Wall Street Journal Best on the Street Stock picking survey in 2010, #3 in the Forbes/Zacks Investment Research Best Analysts for the Drugs category in 2010, and #3 in the pharmaceutical sector by for earnings estimate accuracy in 2007. His investment views have been cited in publications such as the Wall Street Journal and the New York Times, and he has made frequent appearances on CNBC, CBS Marketwatch, and Bloomberg.

Mr. Henry attended the University of Rhode Island and received an M.B.A. from Cornell University.


Joined Roth

February 2008

Sector Focus



University of Rhode Island; M.B.A. from Cornell University


Oppenheimer; Thomas Weisel Partners; ABN AMRO; Leerink Swann & Co.


Drugs Industry No. 3 “Best Brokerage Analyst” Award Forbes/Zacks 2010

Pharmaceuticals No. 2 Master Stock Picker “Best on the Street” Award The Wall Street Journal 2010

Pharmaceuticals No. 3 Top Earnings Estimator Award, FT StarMine 2011

Pharmaceuticals No. 2 Top Stock Picker Award, Thompson Reuters StarMine 2014